JP2018522042A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522042A5 JP2018522042A5 JP2018505479A JP2018505479A JP2018522042A5 JP 2018522042 A5 JP2018522042 A5 JP 2018522042A5 JP 2018505479 A JP2018505479 A JP 2018505479A JP 2018505479 A JP2018505479 A JP 2018505479A JP 2018522042 A5 JP2018522042 A5 JP 2018522042A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- independently
- heterocyclyl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 139
- 125000003118 aryl group Chemical group 0.000 claims description 91
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 82
- 125000000623 heterocyclic group Chemical group 0.000 claims description 77
- 150000001875 compounds Chemical class 0.000 claims description 69
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 50
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 50
- 125000001072 heteroaryl group Chemical group 0.000 claims description 49
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 47
- 125000005884 carbocyclylalkyl group Chemical group 0.000 claims description 45
- 229910052739 hydrogen Inorganic materials 0.000 claims description 37
- 239000001257 hydrogen Substances 0.000 claims description 37
- 229910052799 carbon Inorganic materials 0.000 claims description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 33
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 32
- 150000003839 salts Chemical class 0.000 claims description 31
- 229910052757 nitrogen Inorganic materials 0.000 claims description 21
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
- -1 α-amino acid ester Chemical class 0.000 claims description 20
- 150000002431 hydrogen Chemical class 0.000 claims description 18
- 208000035475 disorder Diseases 0.000 claims description 17
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 15
- 125000004432 carbon atom Chemical group C* 0.000 claims description 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 12
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 12
- 125000006413 ring segment Chemical group 0.000 claims description 12
- 208000017442 Retinal disease Diseases 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 230000015572 biosynthetic process Effects 0.000 claims description 10
- 210000002565 arteriole Anatomy 0.000 claims description 9
- 125000004122 cyclic group Chemical group 0.000 claims description 9
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 208000012268 mitochondrial disease Diseases 0.000 claims description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 8
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 7
- 230000002207 retinal effect Effects 0.000 claims description 7
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 6
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 claims description 6
- 206010070863 Toxicity to various agents Diseases 0.000 claims description 6
- 210000004204 blood vessel Anatomy 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 230000007850 degeneration Effects 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- 229910052740 iodine Inorganic materials 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 5
- 125000006302 indol-3-yl methyl group Chemical group [H]N1C([H])=C(C2=C([H])C([H])=C([H])C([H])=C12)C([H])([H])* 0.000 claims description 5
- 230000004770 neurodegeneration Effects 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 4
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 4
- 125000006736 (C6-C20) aryl group Chemical group 0.000 claims description 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 4
- 208000017164 Chronobiology disease Diseases 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 4
- 230000005856 abnormality Effects 0.000 claims description 4
- 125000004442 acylamino group Chemical group 0.000 claims description 4
- 125000000266 alpha-aminoacyl group Chemical group 0.000 claims description 4
- 208000010668 atopic eczema Diseases 0.000 claims description 4
- 230000033228 biological regulation Effects 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 230000003511 endothelial effect Effects 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 239000003642 reactive oxygen metabolite Substances 0.000 claims description 4
- 125000003003 spiro group Chemical group 0.000 claims description 4
- 125000003107 substituted aryl group Chemical group 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 201000010053 Alcoholic Cardiomyopathy Diseases 0.000 claims description 3
- 201000004569 Blindness Diseases 0.000 claims description 3
- 208000014644 Brain disease Diseases 0.000 claims description 3
- 206010007637 Cardiomyopathy alcoholic Diseases 0.000 claims description 3
- 206010007747 Cataract congenital Diseases 0.000 claims description 3
- 208000009043 Chemical Burns Diseases 0.000 claims description 3
- 230000005778 DNA damage Effects 0.000 claims description 3
- 231100000277 DNA damage Toxicity 0.000 claims description 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 3
- 206010012442 Dermatitis contact Diseases 0.000 claims description 3
- 206010012455 Dermatitis exfoliative Diseases 0.000 claims description 3
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 claims description 3
- 206010013654 Drug abuse Diseases 0.000 claims description 3
- 206010069808 Electrical burn Diseases 0.000 claims description 3
- 208000032274 Encephalopathy Diseases 0.000 claims description 3
- 206010014989 Epidermolysis bullosa Diseases 0.000 claims description 3
- 206010015150 Erythema Diseases 0.000 claims description 3
- 206010015218 Erythema multiforme Diseases 0.000 claims description 3
- 206010015226 Erythema nodosum Diseases 0.000 claims description 3
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 claims description 3
- 206010020649 Hyperkeratosis Diseases 0.000 claims description 3
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 claims description 3
- 208000001126 Keratosis Diseases 0.000 claims description 3
- 201000003533 Leber congenital amaurosis Diseases 0.000 claims description 3
- 208000035172 MERRF Diseases 0.000 claims description 3
- 201000009035 MERRF syndrome Diseases 0.000 claims description 3
- 206010070909 Metabolic cardiomyopathy Diseases 0.000 claims description 3
- 208000009525 Myocarditis Diseases 0.000 claims description 3
- 208000036572 Myoclonic epilepsy Diseases 0.000 claims description 3
- 241000721454 Pemphigus Species 0.000 claims description 3
- 208000034461 Progressive cone dystrophy Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 208000019155 Radiation injury Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 claims description 3
- 206010053615 Thermal burn Diseases 0.000 claims description 3
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 3
- 235000008206 alpha-amino acids Nutrition 0.000 claims description 3
- 210000000709 aorta Anatomy 0.000 claims description 3
- 210000001367 artery Anatomy 0.000 claims description 3
- 201000008937 atopic dermatitis Diseases 0.000 claims description 3
- 230000000747 cardiac effect Effects 0.000 claims description 3
- 210000001715 carotid artery Anatomy 0.000 claims description 3
- 210000003169 central nervous system Anatomy 0.000 claims description 3
- 230000002490 cerebral effect Effects 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 201000008615 cone dystrophy Diseases 0.000 claims description 3
- 208000010247 contact dermatitis Diseases 0.000 claims description 3
- 210000004351 coronary vessel Anatomy 0.000 claims description 3
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims description 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 201000001981 dermatomyositis Diseases 0.000 claims description 3
- 201000009028 early myoclonic encephalopathy Diseases 0.000 claims description 3
- 231100000321 erythema Toxicity 0.000 claims description 3
- 208000004526 exfoliative dermatitis Diseases 0.000 claims description 3
- 210000001105 femoral artery Anatomy 0.000 claims description 3
- 239000000835 fiber Substances 0.000 claims description 3
- 230000001434 glomerular Effects 0.000 claims description 3
- 210000002216 heart Anatomy 0.000 claims description 3
- 208000015210 hypertensive heart disease Diseases 0.000 claims description 3
- 208000022368 idiopathic cardiomyopathy Diseases 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- 208000002780 macular degeneration Diseases 0.000 claims description 3
- 210000003205 muscle Anatomy 0.000 claims description 3
- 210000005036 nerve Anatomy 0.000 claims description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 3
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 3
- 150000002978 peroxides Chemical class 0.000 claims description 3
- 108091008695 photoreceptors Proteins 0.000 claims description 3
- 210000003137 popliteal artery Anatomy 0.000 claims description 3
- 230000000750 progressive effect Effects 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 210000002254 renal artery Anatomy 0.000 claims description 3
- 230000008439 repair process Effects 0.000 claims description 3
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 3
- 208000011117 substance-related disease Diseases 0.000 claims description 3
- 230000036575 thermal burns Effects 0.000 claims description 3
- 239000003053 toxin Substances 0.000 claims description 3
- 231100000765 toxin Toxicity 0.000 claims description 3
- 108700012359 toxins Proteins 0.000 claims description 3
- 230000002792 vascular Effects 0.000 claims description 3
- 230000004393 visual impairment Effects 0.000 claims description 3
- 230000037303 wrinkles Effects 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 206010030875 ophthalmoplegia Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 206010073306 Exposure to radiation Diseases 0.000 claims 2
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 claims 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 150000001450 anions Chemical class 0.000 claims 1
- 208000021090 palsy Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 37
- 239000012453 solvate Substances 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 5
- 125000004450 alkenylene group Chemical group 0.000 description 4
- 125000002947 alkylene group Chemical group 0.000 description 4
- 125000004419 alkynylene group Chemical group 0.000 description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 4
- 208000013016 Hypoglycemia Diseases 0.000 description 3
- 108091005770 SIRT3 Proteins 0.000 description 3
- 102000000478 Sirtuin 3 Human genes 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 208000011731 Abnormal blood glucose concentration Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 0 COC1(C(*)C(C*)OC1)C(C1)C=CC=C1C(*)=O Chemical compound COC1(C(*)C(C*)OC1)C(C1)C=CC=C1C(*)=O 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 235000020934 caloric restriction Nutrition 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 230000032677 cell aging Effects 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000006677 mitochondrial metabolism Effects 0.000 description 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 2
- 239000001301 oxygen Chemical group 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- PIURGAZCVOMJDB-UHFFFAOYSA-N CCC(OCCCC[N]#C)=O Chemical compound CCC(OCCCC[N]#C)=O PIURGAZCVOMJDB-UHFFFAOYSA-N 0.000 description 1
- OINBLAQEQWQJHG-LIUXYNCTSA-O CP(OC[C@H](C(C1)O)O[C@H]1[n+]1cccc(C(N)=O)c1)([I]=C)=O Chemical compound CP(OC[C@H](C(C1)O)O[C@H]1[n+]1cccc(C(N)=O)c1)([I]=C)=O OINBLAQEQWQJHG-LIUXYNCTSA-O 0.000 description 1
- JLKUZTMRIIUTNY-UESOQHSFSA-O CP(OC[C@H](C(C1O)O)O[C@H]1[n+]1cccc(C(N)=O)c1)([I]=C)=O Chemical compound CP(OC[C@H](C(C1O)O)O[C@H]1[n+]1cccc(C(N)=O)c1)([I]=C)=O JLKUZTMRIIUTNY-UESOQHSFSA-O 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 208000001940 Massive Hepatic Necrosis Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 102100026784 Myelin proteolipid protein Human genes 0.000 description 1
- 206010028570 Myelopathy Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 201000005625 Neuroleptic malignant syndrome Diseases 0.000 description 1
- 206010029400 Nicotinic acid deficiency Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 description 1
- 208000002141 Pellagra Diseases 0.000 description 1
- 208000008601 Polycythemia Diseases 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 206010040954 Skin wrinkling Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008727 cellular glucose uptake Effects 0.000 description 1
- 230000010094 cellular senescence Effects 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- 208000025434 cerebellar degeneration Diseases 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000012601 choreatic disease Diseases 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 201000006517 essential tremor Diseases 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000008437 mitochondrial biogenesis Effects 0.000 description 1
- 208000028285 mitochondrial metabolism disease Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562201447P | 2015-08-05 | 2015-08-05 | |
| US62/201,447 | 2015-08-05 | ||
| PCT/US2016/045855 WO2017024255A1 (en) | 2015-08-05 | 2016-08-05 | Nicotinamide mononucleotide derivatives and their uses |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2018522042A JP2018522042A (ja) | 2018-08-09 |
| JP2018522042A5 true JP2018522042A5 (enExample) | 2019-09-19 |
| JP6949002B2 JP6949002B2 (ja) | 2021-10-13 |
| JP6949002B6 JP6949002B6 (ja) | 2021-11-17 |
Family
ID=57944181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018505479A Active JP6949002B6 (ja) | 2015-08-05 | 2016-08-05 | ニコチンアミドモノヌクレオチド誘導体及びそれらの使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (6) | US9855289B2 (enExample) |
| EP (1) | EP3331894B1 (enExample) |
| JP (1) | JP6949002B6 (enExample) |
| KR (1) | KR102354784B1 (enExample) |
| CN (1) | CN108137639B (enExample) |
| AU (1) | AU2016302005B2 (enExample) |
| BR (1) | BR112018002168B1 (enExample) |
| CA (1) | CA2994553C (enExample) |
| DK (1) | DK3331894T3 (enExample) |
| EA (1) | EA035664B1 (enExample) |
| ES (1) | ES2862170T3 (enExample) |
| IL (1) | IL257327B (enExample) |
| MX (1) | MX2018001363A (enExample) |
| PL (1) | PL3331894T3 (enExample) |
| PT (1) | PT3331894T (enExample) |
| WO (1) | WO2017024255A1 (enExample) |
| ZA (1) | ZA201801196B (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9855289B2 (en) | 2015-08-05 | 2018-01-02 | Metro International Biotech, Llc | Nicotinamide mononucleotide derivatives and their uses |
| GB2542881B (en) | 2015-10-02 | 2020-01-01 | Carr Andrew | Crystal forms of ß-nicotinamide mononucleotide |
| US10611790B2 (en) | 2015-11-02 | 2020-04-07 | Mitobridge, Inc. | Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases |
| ES2948968T3 (es) | 2016-04-20 | 2023-09-22 | Chromadex Inc | Uso del ribósido de ácido nicotínico o derivados del ribósido de nicotinamida, y derivados reducidos de los mismos, como precursores que aumentan el NAD++ |
| US20200009170A1 (en) * | 2016-09-13 | 2020-01-09 | Megumi Tanaka | Sleep display agent property and method for improving sleep disorders |
| US20190328761A1 (en) | 2016-12-21 | 2019-10-31 | Newsouth Innovations Pty Limited | Methods for enhancing vascular density |
| US11286274B2 (en) | 2017-06-19 | 2022-03-29 | Mitopower Llc | Nicotinamide riboside derivatives and their uses |
| WO2019152416A1 (en) | 2018-01-30 | 2019-08-08 | Metro International Biotech, Llc | Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof |
| US11814652B2 (en) * | 2018-03-22 | 2023-11-14 | Oriental Yeast Co., Ltd. | Pluripotent stem cell differentiation-promoting agent |
| EP3794005B1 (en) | 2018-05-15 | 2025-10-22 | Jumpstart Fertility Pty Ltd | Inorganic salts of nicotinic acid mononucleotide as anti-aging agents |
| WO2020131578A2 (en) * | 2018-12-17 | 2020-06-25 | Mitopower Llc | Nicotinyl riboside compounds and their uses |
| WO2020174492A1 (en) | 2019-02-25 | 2020-09-03 | Celagenex Research (India) Pvt. Ltd. | Synergistic bioactive compositions for enhancing cellular energy |
| US11939348B2 (en) | 2019-03-22 | 2024-03-26 | Metro International Biotech, Llc | Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide |
| US10618927B1 (en) | 2019-03-22 | 2020-04-14 | Metro International Biotech, Llc | Compositions and methods for modulation of nicotinamide adenine dinucleotide |
| AU2020288608B2 (en) * | 2019-06-05 | 2025-04-10 | Société des Produits Nestlé S.A. | Reduced nicotinamideribosides for the treatment/prevention of liver disease |
| JP7675061B2 (ja) | 2019-07-19 | 2025-05-12 | バイオシント アクチェンゲゼルシャフト | ニコチンアミドリボフラノシド塩の製造方法、ニコチンアミドリボフラノシド塩自体、およびその使用 |
| CN114423439B (zh) | 2019-09-09 | 2024-12-31 | 努瓦米德股份有限公司 | Nmn用于预防和/或治疗疼痛的用途及相应组合物 |
| FR3100449B1 (fr) | 2019-09-09 | 2022-08-26 | Nuvamid Sa | Utilisation de NMN pour la prévention et/ou le traitement de la douleur et compositions correspondantes |
| FR3102058A1 (fr) | 2019-10-18 | 2021-04-23 | Nuvamid Sa | Utilisation de NMN pour la prévention et/ou le traitement de la polyarthrite rhumatoïde et compositions correspondantes |
| CN112823778B (zh) * | 2019-11-21 | 2024-06-14 | 百瑞全球有限公司 | 毛发护理组合物及其制备方法 |
| FR3103702B1 (fr) | 2019-11-28 | 2022-02-11 | Nuvamid Sa | Utilisation de NMN pour la prévention et/ou le traitement de la spondylarthrite ankylosante et compositions correspondantes |
| FR3106056B1 (fr) | 2020-01-13 | 2021-12-17 | Nuvamid | Utilisation de NMN pour la prévention et/ou le traitement d’une douleur articulaire induite par l’activité physique et compositions correspondantes |
| FR3107897B1 (fr) * | 2020-03-06 | 2023-05-26 | Nuvamid Sa | Dérivés de nicotinamide mononucléotides |
| FR3108031B1 (fr) | 2020-03-12 | 2024-02-16 | Nuvamid Sa | Utilisation de NMN pour la prévention et/ou le traitement d’une douleur dorsale et compositions correspondantes |
| FR3108032B1 (fr) * | 2020-03-12 | 2024-02-16 | Nuvamid Sa | Utilisation de NMN pour la prévention et/ou le traitement d’une douleur musculaire, ligamentaire ou tendineuse induite par l’activité physique et compositions correspondantes |
| KR20220160611A (ko) * | 2020-03-30 | 2022-12-06 | 오리엔탈고우보고오교가부시끼가이샤 | 줄기세포의 염색체 안정화제 |
| AU2021260118A1 (en) * | 2020-04-24 | 2022-11-17 | Nuvamid Sa | Nicotinamide mononucleotide and nicotinamide riboside derivatives and use thereof in the treatment of viral infections and respiratory complications, in particular caused by influenzavirus or coronavirus |
| EP3901160A1 (en) * | 2020-04-25 | 2021-10-27 | Nuvamid SA | Nicotinamide mononucleotide and nicotinamide riboside derivatives and use thereof in the treatment of viral infections and respiratory complications, in particular caused by influenzavirus or coronavirus |
| JP7597396B2 (ja) * | 2020-05-05 | 2024-12-10 | コナゲン インコーポレイテッド | 微生物プロセスを介したｎｍｎおよびその誘導体の生成 |
| US20230210746A1 (en) | 2020-05-20 | 2023-07-06 | Nuvamid Sa | Anti-aging cosmetic compositions comprising nmn |
| FR3110410A1 (fr) | 2020-05-20 | 2021-11-26 | Nuvamid Sa | Compositions cosmétiques anti-âge comprenant de la NMN |
| FR3110836B1 (fr) | 2020-05-29 | 2023-06-16 | Nuvamid | Utilisation de NMN pour réduire l’immunodépression et l’immunosénescence |
| CN111548383B (zh) * | 2020-06-11 | 2023-04-18 | 湖南和泰康瑞生物技术有限公司 | 一种β-烟酰胺单核苷酸的工艺制备方法 |
| CN111956670A (zh) * | 2020-08-31 | 2020-11-20 | 杭州伊瑟奇生物科技有限公司 | 一种间充质干细胞及其活性因子复合物冻干品的制备方法 |
| WO2022047779A1 (zh) * | 2020-09-07 | 2022-03-10 | 音芙医药科技(上海)有限公司 | 烟酰胺单核苷酸在制备提高损伤皮肤肌膜中Na+-K+-ATP酶水平试剂中的应用 |
| CN112094362B (zh) * | 2020-09-29 | 2022-04-12 | 四川大学华西医院 | 烟酰胺核糖或单核苷酸类似物-大分子载体轭合物及制法和应用 |
| WO2022094916A1 (zh) * | 2020-11-06 | 2022-05-12 | 中国科学院深圳先进技术研究院 | 一种提高烟酰胺磷酸核糖转移酶活性的方法及其组合物 |
| CN112500445B (zh) * | 2020-12-04 | 2022-11-29 | 黄冈鲁班药业股份有限公司 | β-烟酰胺核糖的制备方法 |
| IT202100005054A1 (it) * | 2021-03-04 | 2022-09-04 | Azienda Ospedaliero Univ Di Parma | Composto farmaceutico per l’uso in un trattamento terapeutico dell’infezione cronica da hbv e metodo per l’identificazione di linfociti esauriti |
| KR102633321B1 (ko) * | 2021-05-11 | 2024-02-05 | 연세대학교 산학협력단 | 노인성 황반변성의 예방 또는 치료를 위한 약학 조성물 |
| CA3219033A1 (en) | 2021-05-27 | 2022-12-01 | Metro International Biotech, Llc | Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and use |
| CN115304655B (zh) * | 2021-11-23 | 2024-11-22 | 中立安(北京)医药科技有限公司 | 烟酰胺单核苷类衍生物及其制备方法和应用 |
| CN118541157A (zh) | 2021-12-22 | 2024-08-23 | 麦德龙国际生物科技有限责任公司 | 用于治疗炎症的组合物 |
| WO2023119230A1 (en) | 2021-12-22 | 2023-06-29 | L'oreal | Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use |
| CN114540283B (zh) * | 2022-01-27 | 2023-10-20 | 中国农业科学院北京畜牧兽医研究所 | 用于牛体外胚胎生产的高效玻璃化冷冻方法 |
| US12065404B2 (en) | 2022-03-18 | 2024-08-20 | Enveric Biosciences Canada Inc. | C4-carboxylic acid-substituted tryptamine derivatives and methods of using |
| CN115611960A (zh) * | 2022-11-18 | 2023-01-17 | 翔鹏(北京)生物科技有限公司 | 一种人体辅酶i前体的制备方法 |
| CN118593362B (zh) * | 2024-06-26 | 2026-05-12 | 山东福瑞达生物股份有限公司 | 一种nmn油悬液的制备方法与应用 |
| WO2026053929A1 (ja) * | 2024-09-06 | 2026-03-12 | 国立大学法人 東京大学 | 細胞内ａｔｐおよび細胞内ｎａｄの量を増加させるための組成物 |
Family Cites Families (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3201389A (en) | 1962-09-24 | 1965-08-17 | Kyowa Hakko Kogyo Kk | Method for preparing ribonucleoside-5'-phosphates or their salts from ribonucleosides |
| US3451997A (en) | 1965-11-30 | 1969-06-24 | Kyowa Hakko Kogyo Kk | Monothio-phosphate ester catalysis for preparation of ribonucleoside derivatives |
| US4411995A (en) | 1981-09-28 | 1983-10-25 | Massachusetts Institute Of Technology | Synthesis of nicotinamide cofactors |
| US5318508A (en) | 1991-03-15 | 1994-06-07 | Elvira Osthold | Nail corrective brace |
| RS20100077A (sr) | 2001-04-30 | 2010-10-31 | Trommsdorff Gmbh. & Co. Kg. Arzneimittel | Farmaceutski aktivni estri uridina |
| US7977049B2 (en) | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| US20040224039A1 (en) | 2003-02-12 | 2004-11-11 | Donald Brucker | Compositions and methods for the treatment of diseases and disorder associated with oxidative damage |
| WO2006072809A2 (en) | 2003-10-31 | 2006-07-13 | Robarts Research Institute | Formulations that optimize intracellular concentration of nicotinamide adenine (nad+) and methods of use to protect cells and treat diseases and conditions |
| CN1964627B (zh) | 2004-06-04 | 2011-10-19 | 华盛顿大学 | 治疗神经病变的方法和组合物 |
| US7998974B2 (en) | 2005-03-03 | 2011-08-16 | Sirtris Pharmaceuticals, Inc. | Fused heterocyclic compounds and their use as sirtuin modulators |
| EP2805719A1 (en) | 2005-03-30 | 2014-11-26 | Glaxosmithkline LLC | Nicotinamide riboside and analogues thereof |
| US20070149466A1 (en) | 2005-07-07 | 2007-06-28 | Michael Milburn | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
| US7855289B2 (en) | 2005-08-04 | 2010-12-21 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| EP1915053A2 (en) | 2005-08-12 | 2008-04-30 | Merck & Co., Inc. | Novel 2'-c-methyl and 4'-c-methyl nucleoside derivatives |
| JP5063878B2 (ja) | 2005-08-30 | 2012-10-31 | 扶桑薬品工業株式会社 | 硫化水素塩を含有する消化器系疾患の予防／治療用組成物 |
| WO2007061798A2 (en) | 2005-11-18 | 2007-05-31 | Cornell Research Foundation, Inc. | Nicotinoyl riboside compositions and methods of use |
| US20080226750A1 (en) | 2006-04-20 | 2008-09-18 | Fred Hutchinson Cancer Research Center | Methods, Compositions and Articles of Manufacture for Treating Shock and Other Adverse Conditions |
| US20080318892A1 (en) | 2006-04-28 | 2008-12-25 | John Geoffrey Pickering | Methods and formulations for protecting cells, and for treating diseases and conditions by optimizing the intracellular concentration of nad |
| CA2676609A1 (en) | 2007-01-26 | 2008-07-31 | Washington University | Methods and compositions for treating neuropathies |
| TW200936146A (en) | 2007-11-29 | 2009-09-01 | Metabasis Therapeutics Inc | Antiviral nucleoside compounds |
| CN101497638B (zh) | 2008-01-30 | 2012-09-26 | 中国科学院大连化学物理研究所 | 一种nad+类似物及其合成和应用 |
| PL2280973T3 (pl) | 2008-04-23 | 2013-05-31 | Gilead Sciences Inc | Analogi karba-nukleozydowe do leczenia przeciwwirusowego |
| US11219696B2 (en) | 2008-12-19 | 2022-01-11 | Nationwide Children's Hospital | Delivery of polynucleotides using recombinant AAV9 |
| CN101601679B (zh) | 2009-03-17 | 2011-08-10 | 中国人民解放军第二军医大学 | 一种烟酰胺单核苷酸的应用 |
| WO2010135520A1 (en) * | 2009-05-20 | 2010-11-25 | Chimerix, Inc. | Compounds, compositions and methods for treating viral infection |
| US20130102009A1 (en) | 2010-04-15 | 2013-04-25 | Han Dai | Sirtuin activators and activation assays |
| TW201201815A (en) | 2010-05-28 | 2012-01-16 | Gilead Sciences Inc | 1'-substituted-carba-nucleoside prodrugs for antiviral treatment |
| US8481711B2 (en) | 2010-07-06 | 2013-07-09 | Hidenori Kamanishi | Neurite outgrowth agent |
| AR082885A1 (es) | 2010-09-03 | 2013-01-16 | Genentech Inc | Compuestos y composiciones para la inhibicion de nampt |
| AR082886A1 (es) | 2010-09-03 | 2013-01-16 | Forma Therapeutics Inc | Compuestos y composiciones farmaceuticas que los contienen |
| CN106986856A (zh) | 2010-09-03 | 2017-07-28 | 福马Tm有限责任公司 | 作为用于治疗疾病诸如癌症的nampt抑制剂的4‑{[(吡啶‑3‑基‑甲基)氨基羰基]氨基}苯‑砜衍生物 |
| WO2012094343A1 (en) * | 2011-01-05 | 2012-07-12 | Trilink Biotechnologies | Chemically substituted thermosensitive probes and cofactors for hot start ligation |
| WO2012114204A2 (en) | 2011-02-15 | 2012-08-30 | Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto | Methods of treating mitochondrial dysfunction |
| US20120107888A1 (en) | 2011-02-17 | 2012-05-03 | Qteros, Inc. | Modulation of fermentation products through vitamin supplementation |
| JP5978293B2 (ja) | 2011-05-04 | 2016-08-24 | フォーマ ティーエム， エルエルシー． | Ｎａｍｐｔを阻害するための新規な化合物および組成物 |
| US20120328526A1 (en) | 2011-06-27 | 2012-12-27 | University Of Maryland, Baltimore | Modulation of Nad+ Activity in Neuropathophysiological Conditions and Uses Thereof |
| EP3345901A3 (en) | 2011-06-29 | 2018-09-12 | President and Fellows of Harvard College | Small molecules as antiaging agents |
| US20130143835A1 (en) | 2011-12-05 | 2013-06-06 | Medivir Ab | HCV Polymerase Inhibitors |
| WO2013127268A1 (en) | 2012-03-02 | 2013-09-06 | Genentech,Inc. | Amido-benzyl sulfone and sulfonamide derivatives |
| WO2013130943A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Alkyl-and di-substituted amido-benzyl sulfonamide derivatives |
| SG10201701894SA (en) | 2012-03-02 | 2017-05-30 | Genentech Inc | Amido-Benzyl Sulfone and Sulfoxide Derivatives |
| HRP20170411T1 (hr) | 2012-03-02 | 2017-06-16 | Genentech, Inc. | Amido spirocilični amidni i sulfonamidni derivati |
| EP2820017B1 (en) | 2012-03-02 | 2016-12-21 | Genentech, Inc. | Pyridinyl and pyrimidinyl sulfoxide and sulfone derivatives |
| MD20140134A2 (ro) | 2012-05-22 | 2015-04-30 | Idenix Pharmaceuticals, Inc. | Compuşi ai D-aminoacizilor pentru tratamentul bolilor hepatice |
| EP2872128B1 (en) | 2012-07-16 | 2020-02-19 | Cornell University | Nicotinamide riboside to treat hearing loss |
| WO2014059034A2 (en) | 2012-10-09 | 2014-04-17 | President And Fellows Of Harvard College | Nad biosynthesis and precursors for the treatment and prevention of cancer and proliferation |
| CN102876759A (zh) | 2012-10-29 | 2013-01-16 | 尚科生物医药（上海）有限公司 | 尼克酰胺腺嘌呤二核苷酸的制备方法 |
| WO2014074715A1 (en) | 2012-11-07 | 2014-05-15 | Genentech, Inc. | Cyclopropyl amide derivatives |
| WO2014111906A1 (en) | 2013-01-21 | 2014-07-24 | Ecole Polytechnique Federale De Lausanne (Epfl) | Bioluminescence imaging of small biomolecules |
| US20140271355A1 (en) | 2013-03-15 | 2014-09-18 | Sabre Intellectual Property Holdings Llc | Apparatus and process for focused gas phase application of biocide |
| WO2014146044A1 (en) | 2013-03-15 | 2014-09-18 | Washington University | Administration of nicotinamide mononucleotide in the treatment of disease |
| GB201313465D0 (en) | 2013-07-29 | 2013-09-11 | Queens University Of The Belfast | Methods of preparing nicotinamide riboside and derivatives thereof |
| WO2015069860A1 (en) | 2013-11-06 | 2015-05-14 | President And Fellows Of Harvard College | Biological production of nad precursors and analogs |
| US10398701B2 (en) | 2013-11-12 | 2019-09-03 | Ortho-Nutra, Llc | Theacrine-based supplement and method of use thereof in a synergistic combination with caffeine |
| BR112016010422B1 (pt) | 2013-11-12 | 2021-08-31 | Ortho-Nutra, Llc | Suplemento dietético e método de tratamento para melhorar o desempenho ou energia física em um indivíduo |
| EP3068364B1 (en) | 2013-11-14 | 2021-11-03 | Metro Biotech NSW Pty Ltd | Nad+ precursor selected from nmn, naad, namn, or a pharmaceutically acceptable salt thereof, for use in treating a side effect of chemotherapy and/or radiotherapy in a subject |
| CN104367587B (zh) | 2013-12-06 | 2018-06-29 | 中国人民解放军第二军医大学 | 烟酰胺单核苷酸在制备促脑缺血后神经再生药物中的应用 |
| US10301268B2 (en) | 2014-03-13 | 2019-05-28 | The Salk Institute For Biological Studies | Analogs of fexaramine and methods of making and using |
| JP2017511304A (ja) | 2014-03-13 | 2017-04-20 | ソーク インスティチュート フォー バイオロジカル スタディーズ | フェキサラミン類似体ならびに作製方法および使用方法 |
| US20150258052A1 (en) | 2014-03-13 | 2015-09-17 | Salk Institute For Biological Studies | Methods of using fexaramine and agents that increase sympathetic nervous system activity to promote browning of white adipose tissue |
| US10316054B2 (en) | 2014-06-02 | 2019-06-11 | Glaxosmithkline Intellectual Property (No. 2) Limited | Preparation and use of crystalline beta-D-nicotinamide riboside |
| EP3151671A4 (en) | 2014-06-03 | 2018-03-07 | Sulfagenix, Inc. | Methods and compositions for treating nitric oxide deficiency disorders and related conditions |
| RU2016149767A (ru) | 2014-06-06 | 2018-07-16 | Глэксосмитклайн Интеллекчуал Проперти (Но.2) Лимитед | Аналоги никотинамидрибозида и фармацевтические композиции и их применение |
| CA2956163C (en) | 2014-07-24 | 2023-01-10 | W.R. Grace & Co.-Conn. | Crystalline form of nicotinamide riboside |
| US10653782B2 (en) | 2014-11-25 | 2020-05-19 | Nortwestern University | Retroviral particles expressing Sirt1 embedded within PPCN |
| WO2016093515A1 (ko) | 2014-12-09 | 2016-06-16 | (주)아모레퍼시픽 | 장수 유전자 활성화용 조성물 |
| ES2963057T3 (es) | 2015-03-09 | 2024-03-25 | Grace W R & Co | Forma cristalina de ribósido de nicotinamida |
| CN104817604B (zh) | 2015-03-16 | 2017-08-04 | 邦泰生物工程(深圳)有限公司 | 一种β‑烟酰胺单核苷酸的纯化方法 |
| EP3271456A1 (en) | 2015-03-18 | 2018-01-24 | The Regents of the University of California | Methods of preventing and reversing stem cell aging |
| US20160355539A1 (en) | 2015-06-04 | 2016-12-08 | Chromadex, Inc. | Selective solvent free phosphorylation |
| US20180177703A1 (en) | 2015-06-25 | 2018-06-28 | N.V. Perricone Llc | Niacinamide Mononucleotide Formulations For Skin Aging |
| US9855289B2 (en) | 2015-08-05 | 2018-01-02 | Metro International Biotech, Llc | Nicotinamide mononucleotide derivatives and their uses |
| TW201713774A (zh) | 2015-08-06 | 2017-04-16 | Kohjin Life Sciences Co Ltd | 含有β-菸鹼醯胺單核苷酸的酵母萃取物及其製造方法 |
| GB2542881B (en) | 2015-10-02 | 2020-01-01 | Carr Andrew | Crystal forms of ß-nicotinamide mononucleotide |
| CA3001483A1 (en) | 2015-10-07 | 2017-04-13 | Joel HUIZENGA | Resetting biological pathways for defending against and repairing deterioration from human aging |
| US10611790B2 (en) | 2015-11-02 | 2020-04-07 | Mitobridge, Inc. | Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases |
| EP3401323B1 (en) | 2015-12-21 | 2020-07-08 | Showa Denko K.K. | Nicotinamide mononucleotide derivative and salt thereof, method for producing the same, topical agent, cosmetic and food additive |
| EP3187180A1 (en) | 2015-12-28 | 2017-07-05 | Ludwig-Maximilians-Universität München | Adenosylhomocysteinase binding substances for medical use |
| US11248018B2 (en) | 2016-02-23 | 2022-02-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Process for preparation of nicotinamide riboside (NR) and cosmetic composition comprising (NR and a phosphate-binding agent |
| EP3429354A4 (en) | 2016-03-16 | 2020-03-25 | Chromadex Inc. | B-VITAMIN AND AMINO ACID CONJUGATES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, DERIVATIVES THEREOF AND METHOD FOR THE PRODUCTION THEREOF |
| ES2948968T3 (es) | 2016-04-20 | 2023-09-22 | Chromadex Inc | Uso del ribósido de ácido nicotínico o derivados del ribósido de nicotinamida, y derivados reducidos de los mismos, como precursores que aumentan el NAD++ |
| WO2017218580A1 (en) | 2016-06-14 | 2017-12-21 | Rejuvenation Therapeutics Corporation | Synthetic methods for the preparation of nicotinamide riboside and related compounds |
| CN107889504B (zh) | 2016-07-30 | 2021-07-27 | 邦泰生物工程(深圳)有限公司 | 一种制备烟酰胺单核苷酸的方法 |
| WO2018023209A1 (zh) | 2016-07-30 | 2018-02-08 | 邦泰生物工程(深圳)有限公司 | 一种制备烟酰胺单核苷酸的方法 |
| WO2017185549A1 (zh) | 2016-07-30 | 2017-11-02 | 邦泰生物工程(深圳)有限公司 | 一种制备烟酰胺单核苷酸的方法2 |
| CN108026132B (zh) | 2016-07-30 | 2021-08-13 | 邦泰生物工程(深圳)有限公司 | 一种烟酰胺单核苷酸的纯化方法 |
| WO2018023208A1 (zh) | 2016-07-30 | 2018-02-08 | 邦泰生物工程(深圳)有限公司 | 一种制备烟酰胺单核苷酸的方法 |
| CN107889505B (zh) | 2016-07-30 | 2021-05-25 | 邦泰生物工程(深圳)有限公司 | 一种制备烟酰胺单核苷酸的方法 |
| WO2018047715A1 (ja) | 2016-09-06 | 2018-03-15 | 協和発酵バイオ株式会社 | β－ニコチンアミドモノヌクレオチドの結晶及びその製造方法 |
| JP7002713B2 (ja) | 2016-09-09 | 2022-01-20 | 日本電気株式会社 | 量子鍵配送システム用の送信装置、受信装置、量子鍵配送方法、および量子鍵配送プログラム |
| US10898738B2 (en) | 2016-09-13 | 2021-01-26 | Megumi Tanaka | Visual function printing agent, and method for improving visual functions |
| US20200009170A1 (en) | 2016-09-13 | 2020-01-09 | Megumi Tanaka | Sleep display agent property and method for improving sleep disorders |
| NZ803738A (en) | 2016-11-11 | 2024-05-31 | Chromadex Inc | Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof |
| US20190328761A1 (en) | 2016-12-21 | 2019-10-31 | Newsouth Innovations Pty Limited | Methods for enhancing vascular density |
| CN106755209B (zh) | 2016-12-29 | 2021-07-23 | 苏州汉酶生物技术有限公司 | 一种酶法制备β-烟酰胺单核苷酸的方法 |
| EP3568488A4 (en) | 2017-01-13 | 2020-09-23 | The Regents of The University of Colorado, A Body Corporate | METHODS OF TREATMENT OF HYPERTENSION AND ARTERIAL RIGIDITY |
| US11634690B2 (en) | 2017-01-31 | 2023-04-25 | Oriental Yeast Co., Ltd. | Agent for accelerating growth of pluripotent stem cells |
| JP6920071B2 (ja) | 2017-02-16 | 2021-08-18 | ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | アディポネクチン分泌向上剤 |
| AU2018250242B2 (en) | 2017-04-05 | 2021-07-15 | Cornell University | Beta-nicotinate ester nucleotides and processes for preparing same |
| AU2018309558A1 (en) | 2017-07-31 | 2020-02-27 | Newsouth Innovations Pty Limited | Methods for increasing fertility |
| WO2019152416A1 (en) | 2018-01-30 | 2019-08-08 | Metro International Biotech, Llc | Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof |
| US20210388018A1 (en) | 2018-10-01 | 2021-12-16 | Cornell University | Methyl and ethyl nicotinate-riboside-5-phosphates, preparation thereof and methods of use thereof |
| KR20210108400A (ko) | 2018-12-10 | 2021-09-02 | 크로마덱스 아이엔씨. | 니코티노일 리보사이드 및 이의 유도체의 결정질 형태 및 이의 제조 방법 |
| CN113811310B (zh) | 2019-03-22 | 2023-03-24 | 麦德龙国际生物科技有限责任公司 | 包括烟酰胺核苷的磷衍生物的组合物以及用于调节烟酰胺腺嘌呤二核苷酸的方法 |
| US10618927B1 (en) | 2019-03-22 | 2020-04-14 | Metro International Biotech, Llc | Compositions and methods for modulation of nicotinamide adenine dinucleotide |
| US11939348B2 (en) | 2019-03-22 | 2024-03-26 | Metro International Biotech, Llc | Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide |
| US20230210746A1 (en) | 2020-05-20 | 2023-07-06 | Nuvamid Sa | Anti-aging cosmetic compositions comprising nmn |
| CA3219033A1 (en) | 2021-05-27 | 2022-12-01 | Metro International Biotech, Llc | Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and use |
-
2016
- 2016-08-05 US US15/512,388 patent/US9855289B2/en active Active
- 2016-08-05 PL PL16833957T patent/PL3331894T3/pl unknown
- 2016-08-05 EP EP16833957.0A patent/EP3331894B1/en active Active
- 2016-08-05 CN CN201680059161.5A patent/CN108137639B/zh active Active
- 2016-08-05 PT PT168339570T patent/PT3331894T/pt unknown
- 2016-08-05 KR KR1020187006160A patent/KR102354784B1/ko active Active
- 2016-08-05 ES ES16833957T patent/ES2862170T3/es active Active
- 2016-08-05 BR BR112018002168-7A patent/BR112018002168B1/pt active IP Right Grant
- 2016-08-05 CA CA2994553A patent/CA2994553C/en active Active
- 2016-08-05 EA EA201890435A patent/EA035664B1/ru unknown
- 2016-08-05 MX MX2018001363A patent/MX2018001363A/es unknown
- 2016-08-05 WO PCT/US2016/045855 patent/WO2017024255A1/en not_active Ceased
- 2016-08-05 AU AU2016302005A patent/AU2016302005B2/en active Active
- 2016-08-05 JP JP2018505479A patent/JP6949002B6/ja active Active
- 2016-08-05 DK DK16833957.0T patent/DK3331894T3/da active
-
2017
- 2017-03-20 US US15/463,683 patent/US9919003B2/en active Active
-
2018
- 2018-01-23 US US15/877,597 patent/US10548913B2/en active Active
- 2018-02-04 IL IL257327A patent/IL257327B/en unknown
- 2018-02-21 ZA ZA2018/01196A patent/ZA201801196B/en unknown
-
2019
- 2019-12-13 US US16/713,711 patent/US11464796B2/en active Active
-
2022
- 2022-07-26 US US17/873,577 patent/US11878027B2/en active Active
-
2023
- 2023-11-21 US US18/516,416 patent/US12485135B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2695521C2 (ru) | Производное изоиндолина, промежуточный продукт, способ получения, фармацевтическая композиция и ее применение | |
| JP2024161353A (ja) | β－ニコチンアミドモノヌクレオチドの結晶形態 | |
| CA3084030A1 (en) | Sulfonamide compounds and use thereof | |
| JP6262732B2 (ja) | Ｎ型カルシウムチャネル遮断剤としての置換ピラゾール | |
| JP6933964B2 (ja) | ヘテロアリール化合物およびそれらの使用方法 | |
| EP4050008A1 (en) | Pyridazinone or pyridazine compound and derivative and pharmaceutical composition thereof | |
| JP2011515337A5 (enExample) | ||
| RU2009147708A (ru) | Производные оксадиазола и их применение в качестве потенцирующих средств метаботропных глутаматных рецепторов-842 | |
| RU2015138801A (ru) | Способы, соединения и композиции для лечения связанных с ангиотензином заболеваний | |
| JP2017002091A (ja) | 置換されたジアミノカルボキサミドおよびジアミノカルボニトリルピリミジン、その組成物、ならびに、それを用いた治療方法 | |
| AU2019245390A1 (en) | Mono-(acid) salts of 6-aminoisoquinolines and uses thereof | |
| BR112018002168A2 (en) | nicotinamide mononucleotide derivatives and their uses | |
| CA3165223A1 (en) | Novel nicotinamide di-nucleotide derivatives and use thereof | |
| JP2017524003A (ja) | 薬物耐性癌の治療で用いるための脂肪酸シンターゼ阻害剤 | |
| JP2021522327A5 (enExample) | ||
| CA3243254A1 (en) | HETEROCYCLIC CYCLICAL COMPOUND FUSIONED WITH AN AROMATIC RING USED AS A POTASSIUM CHANNEL REGULATOR, ITS PREPARATION AND USE | |
| JP2015520748A (ja) | 炭酸脱水酵素活性の抑制のための組成物及び方法 | |
| JP7264158B2 (ja) | 神経細胞内カルシウム濃度上昇抑制剤 | |
| EP2124948A1 (en) | Compositions for treating hyperproliferative vascular disorders and cancers | |
| RU2005135850A (ru) | Замещенные изохромановые соединения для лечения метаболических расстройств, рака и другие заболеваний | |
| UA113288C2 (xx) | Trpv1 антагоністи, що містять дигідроксизамісник, і їх застосування | |
| JP2021535907A (ja) | ピラゾロピリミジン誘導体及びそのｐｉ３ｋ抑制剤とする適用 | |
| RU2276138C2 (ru) | Вещество, обладающее антиоксидантной, геропротекторной и противоишемической активностью, и способ его получения | |
| HUE027375T2 (en) | Phenyl guanidine derivatives | |
| JPWO2017072984A1 (ja) | 筋萎縮性疾患治療剤 |